We are pleased to partner with 2bPrecise to enable their pharmacogenomics solution and precision medicine platform, supporting the integration of clinical knowledge and genomic intelligence for patient-specific insights.

First-of-Its-Kind Solution Enables Physicians to Prescribe Medications Based on Genomic Insights in Real Time

PITTSBURGH–(BUSINESS WIRE)–2bPrecise™, an EHR-agnostic, cloud-based precision medicine platform, has launched its pharmacogenomics (PGx) solution to bring critical data to the clinical workflow in real time. 2bPrecise PGx™ makes pharmacogenetic information accessible and actionable so physicians can make informed treatment decisions based on a patient’s unique genetic makeup. 2bPrecise has partnered with Translational Software, Inc. (TSI), a leader in the intelligent use of genomic data for clinical decision support, to leverage its knowledge-base of PGx content.

The National Institutes of Health (NIH) reports that adverse drug events result in more than 770,000 injuries and deaths each year, underscoring the importance of PGx for individualizing therapy. The 2bPrecise PGx solution uniquely plugs into the EHR’s native workflow and can integrate content from TSI and other knowledge sources to enable decision-making at the point of care. 2bPrecise’s PGx solution is part of its larger precision medicine platform, built to capture and store genomic data from a range of sources, enabling the harmonization of clinical knowledge and genomic research to extract patient-specific insights. 2bPrecise’s unique approach to clinical workflow integration and dynamic content connectivity sets it apart from others in the pharmacogenomics space and helps future-proof healthcare organizations as genomic science advances.

“What’s exciting about our partnership with 2bPrecise is that its technology pushes live, real-time PGx content beyond the lab, directly into the clinical setting,” said Don Rule, founder and CEO of Translational Software. “PGx data is no longer limited to a static interpretation at the time of result, allowing delivery of rich genomic insights to clinicians for more precisely diagnosing and treating their patients.”

Read more…